Table 2.
Multivariable logistic regression model of predictors of IMRT use.
| IMRT | |
|---|---|
| Age (years) | |
| 65-69 | Referent |
| 70-74 | 0.93 (0.68.1.27) |
| 75-79 | 0.94 (0.67-1.31) |
| ≥80 | 1.27 (0.92-1.75) |
| Race | |
| White | Referent |
| Black | 1.07 (0.71-1.61) |
| Hispanic | 0.28 (0.07-1.12) |
| Other | 0.88 (0.53-1.46) |
| Year of diagnosis | |
| 2001 | Referent |
| 2002 | 2.36 (1.02-5.47)* |
| 2003 | 3.49 (1.58-7.72)* |
| 2004 | 6.50 (2.98-14.19)* |
| 2005 | 5.91 (2.69-12.98)* |
| 2006 | 11.60 (5.48-24.58)* |
| 2007 | 15.26 (7.26-32.08)* |
| Marital status | |
| Married | Referent |
| Unmarried | 0.87 (0.69-1.10) |
| Unknown | 1.23 (0.67-2.26) |
| Area of residence | |
| Non-metropolitan | Referent |
| Metropolitan | 1.50 (0.97-2.33) |
| SEER registry | |
| Eastern | Referent |
| Midwest | 1.74 (1.25-2.41)* |
| West | 2.23 (1.63-3.04)* |
| Socioeconomic status | |
| Lowest (first) quintile | Referent |
| Second quintile | 1.05 (0.73-1.52) |
| Third quintile | 0.79 (0.54-1.15) |
| Fourth quintile | 0.76 (0.51-1.14) |
| Highest (fifth) quintile | 0.78 (0.52-1.16) |
| Comorbidity score | |
| 0 | Referent |
| 1 | 0.95 (0.73-1.23) |
| ≥2 | 1.06 (0.80-1.41) |
| Tumor histology | |
| Endometrioid | Referent |
| Serous | 0.71 (0.46-1.10) |
| Clear cell | 0.70 (0.32-1.52) |
| Carcinosarcoma | 0.70 (0.44-1.11) |
| Leiomyosarcoma | 0.61 (0.23-1.62) |
| Other/unknown | 0.62 (0.42-0.92)* |
| Stage1 | |
| IA | Referent |
| IB | 0.91 (0.39-2.11) |
| IC | 0.79 (0.35-1.78) |
| INOS | 1.17 (0.50-2.70) |
| II | 0.97 (0.43-2.18) |
| III | 1.13 (0.52-2.46) |
| IV | 0.68 (0.28-1.63) |
| Unknown | |
| Tumor grade | |
| 1 | Referent |
| 2 | 0.85 (0.61-1.20) |
| 3 | 0.89 (0.63-1.24) |
| Unknown | 1.02 (0.67-1.54) |
| Hysterectomy | |
| No | Referent |
| Yes | 0.93 (0.62-1.39) |
| Lymphadenectomy | |
| No | Referent |
| Yes | 1.03 (0.76-1.39) |
| Brachytherapy | |
| No | Referent |
| Yes | 0.82 (0.65-1.03) |
| Chemotherapy | |
| No | Referent |
| Yes | 1.75 (1.36-2.25)* |
FIGO (International Federation of Obstetrics and Gynecology) 1998 staging criteria.
SEER=Surveillance, Epidemiology, and End Results. IMRT=intensity-modulated radiation therapy.
*
P<0.005